The effect of probiotics on childhood constipation: a randomized controlled double blind clinical trial

M Sadeghzadeh1, A Rabieefar2, P Khoshnevisasl3

  • 1Department of Pediatrics, Zanjan Metabolic Disease Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

Insights

Probiotics significantly improved stool frequency and consistency in constipated children after four weeks. Early improvements in incontinence and pain were noted but not sustained long-term.

Area of Science:

  • Pediatric Gastroenterology
  • Microbiome Research

Background:

  • Existing research on probiotics for childhood constipation yields inconsistent results.
  • This study addresses the need for clearer evidence on probiotic efficacy.

Purpose of the Study:

  • To evaluate the effectiveness of probiotics as an adjunct therapy for constipation in children.
  • To compare outcomes in children receiving lactulose plus probiotics versus lactulose plus placebo.

Main Methods:

  • A randomized, placebo-controlled trial involving 56 children aged 4-12 years with constipation.
  • Participants received daily lactulose with either Protexin (probiotic) or placebo for four weeks.
  • Outcomes measured included stool frequency, consistency, abdominal pain, fecal incontinence, and weight gain.

Main Results:

  • Forty-eight children completed the study.
  • Significant improvements in stool frequency (P=0.042) and consistency (P=0.049) were observed by week four.
  • Early improvements in fecal incontinence (P=0.030) and abdominal pain (P=0.017) at week one were not significant by week four.
  • Significant weight gain was noted by week one in the probiotic group.

Conclusions:

  • Probiotics play a beneficial role in enhancing stool frequency and consistency in constipated children by the end of a four-week treatment period.
  • While short-term symptom relief was observed, long-term benefits require further investigation.

Related Concept Videos

Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
296
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
61
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
900
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives01:22

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
904